Jade Biosciences (JBIO) Total Current Liabilities (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of Total Current Liabilities data on file, last reported at $22.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 822.3% year-over-year to $22.3 million; the trailing twelve-month figure through Mar 2026 stood at $22.3 million (up 822.3% YoY), and the FY2025 full-year result was $16.5 million, up 37.87% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $22.3 million, up from $16.5 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $22.4 million in Q3 2025 and bottomed at $2.4 million in Q1 2025.
• The 5-year median for Total Current Liabilities is $13.3 million (2023), against an average of $13.0 million.
• The widest annual swing landed in 2025, when Total Current Liabilities sank 84.42%; it then jumped 822.3% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $7.8 million in 2022, then soared by 126.64% to $17.6 million in 2023, then plunged by 31.98% to $12.0 million in 2024, then surged by 37.87% to $16.5 million in 2025, then soared by 34.78% to $22.3 million in 2026.
• The last three Total Current Liabilities figures came in at $22.3 million (Q1 2026), $16.5 million (Q4 2025), and $22.4 million (Q3 2025), per Business Quant data.

Peer Comparison